Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials

No abstract is available for this paper.

• Publication year

  2011

• Venue

  International Clinical Psychopharmacology

• Publication date

  2011-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/YIC.0b013e3283430a0ePMID 21372722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.

  2025cited by this paper
• Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial

  2011cited by this paper
• Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.

  2011cited by this paper
• Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study.

  2011influential reference
• Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.

  2010cited by this paper
• Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.

  2010cited by this paper
• Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo‐controlled trial

  2010cited by this paper
• Cholesterol and triglycerides in antipsychotic-naive patients with nonaffective psychosis.

  2010cited by this paper
• Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial

  2010influential reference
• Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2

  2010cited by this paper
• A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

  2010cited by this paper
• Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[¹⁸F]FMeNER-D₂

  2010cited by this paper
• Quetiapine blocks cocaine-induced enhancement of brain stimulation reward.

  2010cited by this paper
• A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).

  2010cited by this paper
• Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.

  2010influential reference
• A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.

  2010cited by this paper
• Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.

  2009cited by this paper
• Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

  2009cited by this paper
• Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

  2009cited by this paper
• Efficacy of treatments for patients with obsessive‐compulsive disorder: A systematic review

  2009cited by this paper
• The dopamine hypothesis of schizophrenia: version III--the final common pathway.

  2009cited by this paper
• Psychosis: A Category or a Dimension?

  2009cited by this paper
• Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

  2009influential reference
• The role of dopamine in bipolar disorder.

  2009cited by this paper
• Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study

  2009influential reference
• Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.

  2009cited by this paper
• Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.

  2009cited by this paper
• Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials

  2009cited by this paper
• Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.

  2009influential reference
• A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder

  2008cited by this paper
• Quetiapine Addition to Serotonin Reuptake Inhibitors in Patients With Severe Obsessive-Compulsive Disorder: A Double-Blind, Randomized, Placebo-Controlled Study

  2008cited by this paper
• N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity

  2008influential reference
• Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings

  2008cited by this paper
• P.1.e.019 PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects

  2008cited by this paper
• Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

  2008cited by this paper
• Quetiapine in patients with borderline personality disorder: an open-label trial.

  2008cited by this paper
• The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: A preliminary trial

  2008cited by this paper
• Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines

  2008cited by this paper
• Quetiapine: dose-response relationship in schizophrenia.

  2008cited by this paper
• Blockade of 5-HT2a Receptors Reduces Haloperidol-Induced Attenuation of Reward

  2007cited by this paper
• Quetiapine for the treatment of borderline personality disorder; an open-label study.

  2007cited by this paper
• Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo‐controlled pilot study

  2007cited by this paper
• Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study.

  2007cited by this paper
• A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania

  2007cited by this paper
• Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel‐group, open study

  2007cited by this paper
• Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.

  2007influential reference
• 5-HT7 receptor antagonists as a new class of antidepressants.

  2007cited by this paper
• Quetiapine: a review of its use in the treatment of bipolar depression.

  2007cited by this paper
• Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression: A Double-blind, Placebo-controlled Study (The BOLDER II Study)

  2006cited by this paper
• A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.

  2006influential reference
• Azapirones for generalized anxiety disorder.

  2006cited by this paper
• Hallucinations in bipolar disorder: characteristics and comparison to unipolar depression and schizophrenia.

  2005cited by this paper
• P.3.115 Rapid versus conventional titration of quetiapine in acute schizophrenia

  2005cited by this paper
• Adding quetiapine to SRI in treatment-resistant obsessive–compulsive disorder: a randomized controlled treatment study

  2005influential reference
• A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder.

  2005influential reference
• Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

  2005cited by this paper
• Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial.

  2005cited by this paper
• A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.

  2005influential reference
• Strategies for producing faster acting antidepressants.

  2005cited by this paper
• Quetiapine Versus Placebo in Combination With Lithium or Divalproex for the Treatment of Bipolar Mania

  2004cited by this paper
• Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study.

  2004cited by this paper
• A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

  2004influential reference
• Quetiapine augmentation in patients with treatment resistant obsessive–compulsive disorder: a single-blind, placebo-controlled study

  2002cited by this paper
• Use of general medical services by VA patients with psychiatric disorders.

  2002cited by this paper
• Deconstructing current comorbidity: data from the Australian National Survey of Mental Health and Well-Being

  2002cited by this paper
• Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

  2001cited by this paper
• Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

  1997cited by this paper
• Use of medical services by veterans with mental disorders.

  1997cited by this paper
• Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.

  1997cited by this paper
• Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

  1996cited by this paper
• Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

  1996cited by this paper
• ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group.

  1996cited by this paper
• Cholesterol and Mental Disorder

  1996cited by this paper
• ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia.

  1995cited by this paper
• Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

  1990cited by this paper
• Brain dopamine and reward.

  1989cited by this paper
• High-v . low-dose quetiapine in schizophrenia : meta-analysis

  year unknowncited by this paper

• Dose-dependent pharmacological mechanisms within the Neuroscience-based Nomenclature: a new concept to facilitate neuroscience-based prescribing.

  2026cites this paper
• Metabolic Adverse Effects of Low‐Dose Quetiapine: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Antipsychotic-Induced Weight Gain: What Have We Learned?

  2025cites this paper
• Repeated Pisa Syndrome Induced Successively by Risperidone, Olanzapine, and Quetiapine in a Female Patient With Dementia.

  2024cites this paper
• Prevalence and risk factors for metabolic syndrome in schizophrenia, schizoaffective, and bipolar disorder

  2024cites this paper
• Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review

  2024cites this paper
• Doses, serum concentrations and diagnoses of Norwegian quetiapine users 2001–2019 in a therapeutic drug monitoring material

  2024cites this paper
• Post‐therapy plasma concentrations of quetiapine in Taiwanese patients

  2023cites this paper
• Brazilian Psychiatric Association treatment guidelines for generalized anxiety disorder: perspectives on pharmacological and psychotherapeutic approaches

  2023cites this paper
• Dose-Dependent Biphasic Action of Quetiapine on AMPK Signalling via 5-HT7 Receptor: Exploring Pathophysiology of Clinical and Adverse Effects of Quetiapine

  2022cites this paper
• Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials.

  2022cites this paper
• Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real‐World Observational Study

  2022cites this paper
• [On the treatment of bipolar affective disorder].

  2022cites this paper
• Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach

  2022cites this paper
• Associations between off-label low-dose olanzapine or quetiapine and cardiometabolic mortality.

  2021cites this paper
• Quetiapine abuse - myth or reality?

  2020cites this paper
• Kvetiapinmisbruk – myte eller realitet?

  2020cites this paper
• Benzodiazepines and antipsychotics in severe mental illness Optimizing and characterizing prescribing practice

  2019cites this paper
• General Principles of Psychopharmacology

  2018cites this paper
• Development of a Typology of Antidepressant Users: The Role of Mental Health Disorders and Substance Use.

  2016cites this paper
• Quetiapine safety in older adults: a systematic literature review

  2016cites this paper
• Post authorization safety study comparing quetiapine to risperidone and olanzapine

  2016cites this paper
• DRAFT Health Care Guideline Depression in Primary Care

  2016cites this paper
• Cannabinoids and obsessive-compulsive disorder

  2015cites this paper
• Who pioneered the use of antipsychotics in North America?

  2015cites this paper
• Anxiety in Patients with Schizophrenia: Epidemiology and Management

  2015cites this paper
• A Literature Review of Quetiapine for Generalized Anxiety Disorder

  2015cites this paper
• Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison

  2015cites this paper
• Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review)

  2015cites this paper
• Effects of repeated quetiapine treatment on conditioned avoidance responding in rats.

  2015cites this paper
• Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison

  2014cites this paper
• Controversies in the use of second generation antipsychotics as sleep agent.

  2014cites this paper
• Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.

  2014cites this paper
• Typology of sleep medication users and associated mental health and substance use from a Montreal epidemiological study.

  2014cites this paper
• Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair

  2013cites this paper
• Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia

  2013cites this paper
• Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.

  2013cites this paper
• Hypothetical dopamine dynamics in mania and psychosis--its pharmacokinetic implications.

  2013influential citation
• [Factors associated with high exposure to psychotropic drugs in a Montreal catchment epidemiological area].

  2013cites this paper
• Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study.

  2013cites this paper
• The ARIQUELI study: potentiation of quetiapine in bipolar I nonresponders with lithium versus aripiprazole

  2013cites this paper
• Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.

  2013cites this paper
• Facteurs associés à l’exposition élevée aux médicaments psychotropes identifiés lors d’une étude épidémiologique montréalaise

  2013cites this paper
• Psychiatric and neurological symptoms in schizophrenia and substance use disorder patients treated for 12-weeks with quetiapine

  2012cites this paper
• Original article Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study

  2012cites this paper
• Comparing tolerability profile of second generation antipsychotics in schizophrenia and affective disorders : a meta-analysis

  2012cites this paper
• Quetiapine for bipolar depression: a systematic review and meta-analysis

  2012cites this paper
• Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia

  2012cites this paper
• Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis

  2012influential citation
• Add-on Treatment of Quetiapine for Fibromyalgia: A Pilot, Randomized, Double-Blind, Placebo-Controlled 12-Week Trial

  2012cites this paper
• Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study

  2012cites this paper
• Plasma Concentrations of Quetiapine, N-Desalkylquetiapine, O-Desalkylquetiapine, 7-Hydroxyquetiapine, and Quetiapine Sulfoxide in Relation to Quetiapine Dose, Formulation, and Other Factors

  2012cites this paper
• Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders

  2012cites this paper
• Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review

  2012cites this paper
• Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case–Control Trial with Quetiapine

  2011cites this paper
• Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile.

  2011cites this paper
• Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

  2009cites this paper